

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

**INSIDE INFORMATION
POTENTIAL MASTER DISTRIBUTION ARRANGEMENT WITH
SICHUAN HUIYU PHARMACEUTICAL CO., LTD.**

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the **“Company”**), together with its subsidiaries, the **“Group”**) pursuant to the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Listing Rules”**).

The board (the **“Board”**) of directors (the **“Directors”**) of the Company has noted that on August 26, 2025, Sichuan Huiyu Pharmaceutical Co., Ltd. (四川匯宇製藥股份有限公司, **“Sichuan Huiyu”**) published an announcement in connection to its board of director's approval of a potential master distribution agreement for TY-9591 (a core product of the Company) to be entered between Sichuan Huichenxin Pharmaceutical Co., Ltd. (四川匯辰昕藥業有限公司, **“Sichuan Huichenxin”**), a wholly-owned subsidiary of Sichuan Huiyu, and the Company (the **“Potential Master Distribution”**). Pursuant to the Potential Master Distribution, the Company may agree to make Sichuan Huichenxin the master distributor for TY-9591 in the People's Republic of China (excluding Hong Kong, Macau, Taiwan and any other overseas regions) on an exclusive basis for an initial milestone payment of up to RMB150 million.

The Company and Sichuan Huichenxin is currently in discussion relating to the other commercial terms for the Potential Master Distribution, including but not limited to the milestone, payment schedule for Sichuan Huichenxin's payment obligations and the initial term of the Potential Master Distribution and the current proposal of the Potential Master Distribution is not legally binding on either party.

Reasons for and benefits of the Potential Master Distribution

The Group is about to enter into a commercialization stage with TY-9591 and the Potential Master Distribution will, if materialized, enable the Group to leverage on the established and extensive sales and distribution network of Sichuan Huichenxin and Sichuan Huiyu, who is a well established full-cycle pharmaceutical company with extensive experience in the distribution and sales of pharmaceutical products in China. The Company is of the view that such arrangement could therefore boost the sales and revenue that the Group may generate from TY-9591, enhancing the market penetration, reducing the Group's cost for setting up new sales channel and strengthen the Group's brand image through collaboration with a well established pharmaceutical company.

Information about Sichuan Huichenxin and Sichuan Huiyu

Sichuan Huichenxin is a wholly-owned subsidiary of Sichuan Huiyu. Sichuan Huiyu is a company listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688553), and it is primarily engaged in the research, development, production and sales of anti-tumor and injection drugs. Mr. Ding Zhao, a former non-executive Director who resigned on March 27, 2025 is the chairman of Sichuan Huiyu and also its beneficial controller. Therefore, Sichuan Huiyu is an associate of a connected person of the Company.

Information about TY-9591

TY-9591 is a tyrosine kinase inhibitor (TKI) developed for, and demonstrates significant efficacy in, patients with brain metastases from lung cancer with epidermal growth factor receptor (“EGFR”) mutations. TY-9591 is able to effectively cross the blood-brain barrier to irreversibly bind EGFR mutants (including exon 19 deletion and exon 21 L858R mutation: exon 19 deletion/T790M mutation and L858R/T790M mutation), and ultimately inhibit the proliferation and metastasis of cancer cells. TY-9591 was developed through modifications of osimertinib to enhance its safety, allowing for a higher administration dosage and thus, potentially, improved efficacy.

General Information

The Board would like to emphasize that negotiations in connection with the Potential Master Distribution is ongoing. The terms of the Potential Master Distribution are subject to the terms of any final agreement that may be entered into between the Sichuan Huiyu and the Company from time to time. If any transaction under the Potential Master Distribution materializes, such transaction may constitute a connected transaction under Chapter 14A of the Listing Rules. The Company will comply with the applicable requirements of the Listing Rules and will make further announcements in accordance with the Listing Rules in due course.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Warning Statement under Rule 18A.05 of the Listing Rules: There is no assurance that the Company will be able to develop, market and/or commercialize TY-9591 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. WU Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong, August 26, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Dr. MENG Xiaoying, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.